@article{oai:repo.qst.go.jp:00045862,
 author = {Hamada, Nobuyuki and Imaoka, Tatsuhiko and Masunaga, Shinichiro and Ogata, Toshiyuki and Okayasu, Ryuichi and Takahashi, Akihisa and Kato, Takamitsu and Kobayashi, Yasuhiko and Ohnishi, Takeo and Ono, Koji and Shimada, Yoshiya and Teshima, Teruki and 浜田 信行 and 今岡 達彦 and 増永 慎一郎 and 尾方 俊至 and 岡安 隆一 and 高橋 昭久 and 加藤 宝光 and 大西 武雄 and 小野 公二 and 島田 義也 and 手島 昭樹},
 issue = {4},
 journal = {Journal of Radiation Research},
 month = {Jul},
 note = {Superb biological effectiveness and dose conformity represent a rationale for heavy-ion therapy, which has thus far achieved good cancer controllability while sparing critical normal organs. Immediately after irradiation, heavy ions produce dense ionization along their trajectories, cause irreparable clustered DNA damage, and alter cellular ultrastructure. These ions, as a consequence, inactivate cells more effectively with less cell-cycle and oxygen dependence than conventional photons. The modes of heavy ion-induced cell death/inactivation include apoptosis, necrosis, autophagy, premature senescence, accelerated differentiation, delayed reproductive cell death of progeny cells, and bystander cell death. This paper briefly reviews the current knowledge of the biological aspects of heavy-ion therapy, with emphasis on the authors' recent findings. The topics include (i) repair mechanisms of heavy ion-induced DNA damage, (ii) superior effects of heavy ions on radioresistant tumors/cells (intratumor quiescent cell population, TP53-mutated and BCL2-overexpressing tumors), (iii) novel capacity of heavy ions in suppressing cancer metastasis and neoangiogenesis, and (iv) potential of heavy ions to induce secondary (especially breast) cancer.},
 pages = {365--383},
 title = {Recent advances in the biology of heavy-ion cancer therapy},
 volume = {51},
 year = {2010}
}